MedTrace Logo

A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease

NCT00256204 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1174

Last updated 2012-01-12

Study results available
· View outcomes & findings →

Summary

A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline

Conditions

Interventions

DRUG

Rasagiline Mesylate

tablet, 1mg once daily

DRUG

Rasagiline Mesylate

tablet, 2mg once daily

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Yoni Weiss, MD · Teva Branded Pharmaceutical Products R&D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2008-04-30
Completion
2009-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00256204 on ClinicalTrials.gov